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S U M M A R Y
Background: The new biochemical marker, signal peptide-CUB-EGF domain-containing protein 1
(SCUBE1), is secreted and cell surface glycoprotein expressed during early embryogenesis. The protein is
found in platelet and endothelial cells. Crimean-Congo hemorrhagic fever (CCHF), which is caused by a
tick-borne virus belonging to the Bunyaviridae family, may present with a mild clinical course or may
exhibit a severe proﬁle with potentially fatal hemorrhaging. The aim of this study was to determine the
diagnostic and prognostic signiﬁcance of SCUBE1 levels in CCHF.
Methods: This study was conducted with patients with CCHF. SCUBE1 levels in patients with CCHF were
determined using an ELISA.
Results: SCUBE1 titers of CCHF patients were signiﬁcantly higher compared to those of the control group
(p = 0.0001). SCUBE1 levels of patients with hemorrhage were signiﬁcantly higher than those of patients
without hemorrhage (p = 0.0001). SCUBE1 values of patients who died were signiﬁcantly higher than
those of the survivors (p = 0.012).
Conclusions: SCUBE1 levels are a new biomarker that can be used in the differential diagnosis and
monitoring of patients hospitalized with suspected CCHF. These levels are also signiﬁcant as potential
predictors of mortality.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The new biochemical marker, signal peptide-CUB-EGF domain-
containing protein 1 (SCUBE1), is secreted and cell surface
glycoprotein expressed during early embryogenesis. The protein
is found in platelet and endothelial cells.1 It contains nine EGF-like
domains and one CUB domain at the carboxyl terminus. Secreted
SCUBE1 can form oligomers and stably associates with the cell
surface. Tu et al. reported that SCUBE1 is stored in the alpha-
granules and is translocated to the surface upon platelet
stimulation. SCUBE genes are present in the human, mouse, and
zebraﬁsh, suggesting that they are evolutionarily conserved and
may have critical biological functions.2 Potential roles and
applications of plasma SCUBE1 levels in acute coronary syndrome
and acute ischemic stroke have been shown by Dai et al.3
Crimean-Congo hemorrhagic fever (CCHF), which is caused by a
tick-borne virus belonging to the Bunyaviridae family, may present* Corresponding author. Tel.: +90 462 377 78 76; fax: +90 462 377 53 44.
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potentially fatal hemorrhaging.4,5 CCHF is a fatal viral infection
described in parts of Africa, Asia, Eastern Europe, and the Middle
East.6 Patients mostly present with complaints such as fever,
fatigue, generalized pain, myalgia, nausea, and vomiting, while
severe cases exhibit epistaxis, hematemesis, melena, hematuria,
gingival bleeding, vaginal bleeding, petechiae, or ecchymosis.4,7
The main target of the CCHF virus is the mononuclear phagocyte
system and endothelial cells.4
SCUBE1 may therefore be considered a diagnostic and
prognostic marker for infectious diseases that impact on endothe-
lial cells and platelets. The aim of this study was to determine the
diagnostic and prognostic signiﬁcance of SCUBE1 levels in CCHF.
2. Materials and methods
2.1. Study population
This retrospective study was conducted with patients with
CCHF hospitalized between 2008 and 2011 at the Department of
Infectious Diseases and Clinical Microbiology of the Faculty ofses. Published by Elsevier Ltd. All rights reserved.
Figure 1. ROC curve analysis of CCHF patients’ SCUBE1 values.
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consent was obtained from all patients and controls, and the
study was approved by the local ethics committee. Blood samples
were taken from subjects who were admitted to the hospital with a
suspicion of CCHF, and patients who were diagnosed as having
CCHF were included in the study. Blood samples were taken and
collected until the day of measurement. SCUBE1 measurements
were performed only in these blood samples. Patients whose CCHF
diagnoses were conﬁrmed through the detection of IgM using an
ELISA and/or the genomic segment of the virus using real-time PCR
(RT-PCR) in the Virology Laboratory of the Reﬁk Saydam National
Hygiene Center of the Turkish Ministry of Health, were enrolled.
The presence of CCHF-speciﬁc serum IgM antibodies was deter-
mined using an in-house ELISA method. The antigens used in the
ELISA tests were obtained from the Centers for Disease Control and
Prevention (CDC, Atlanta, GA, USA). Demographic characteristics,
occupation, tick exposure history, incubation time, symptoms,
duration between onset of symptoms and admission, clinical
ﬁndings, and laboratory tests (white blood cell count (WBC),
platelet count (PLT), hemoglobin (Hb), aspartate aminotransferase
(AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH),
creatine phosphokinase (CPK), myoglobin (Mb), blood urea nitrogen
(BUN), plasma creatinine (Cr), C-reactive protein (CRP), prothrombin
time (PT), activated partial thromboplastin time (aPTT), interna-
tional normalized ratio (INR), and D-dimer) of all patients were
recorded on forms at admission. The control group was formed of
companions of the CCHF patients in our clinic in 2011.
2.2. Determination of SCUBE1 levels
Levels of SCUBE1 were determined using an ELISA kit (Cusabio
Biotech Co., Catalog No. CSB-E15005 h, PR China), in accordance
with the manufacturer’s instructions. The absorbance of samples
was measured at 450 nm using a VERSA max tunable microplate
reader (Molecular Devices, CA, USA). The results were expressed in
ng/ml. The minimum detectable dose of human SCUBE1 is typically
less than 0.16 ng/ml.
2.3. Statistical analysis
A descriptive statistical analysis was performed for all
parameters. The Kolmogorov–Smirnov test was used for theTable 1
Correlation analysis between SCUBE1 and other laboratory parameters
Biochemical markers Mean  SD Correlation analysis
(SCUBE1)
SCUBE1 (ng/ml) 272.0  89.0 r = 1
WBC ( 109/l) 2.852  2.019 r = 0.096; p = 0.409
Hb (g/dl) 13.7  1.7 r = 0.039; p = 0.736
PLT ( 109/l) 82.900  48.129 r = 0.488; p = 0.0001
AST (U/l) 211  403 r = 0.282; p = 0.014
ALT (U/l) 113  163 r = 0.341; p = 0.003
CPK (U/l) 672  1058 r = 0.348; p = 0.002
LDH (U/l) 776  560 r = 0.370; p = 0.001
Mb (g/dl) 156  291 r = 0.145; p = 0.227
BUN (mg/dl) 17.8  13.4 r = 0.357; p = 0.002
Cr (mg/dl) 0.9  0.3 r = 0.456; p = 0.0001
CRP (mg/dl) 2.0  2.7 r = 0.002; p = 0.985
PT (s) 13.9  2.6 r = 0.188; p = 0.104
aPTT (s) 35.8  9.1 r = 0.421; p = 0.0001
INR 1.2  0.2 r = 0.161; p = 0.165
D-dimer (mg/ml) 5.5  9.2 r = 0.384; p = 0.001
ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST,
aspartate aminotransferase; BUN, blood urea nitrogen; CPK, creatine phosphoki-
nase; Hb, hemoglobin; Cr, plasma creatinine; CRP, C-reactive protein; INR,
international normalized ratio; LDH, lactate dehydrogenase; Mb, myoglobin;
PLT, platelet count; PT, prothrombin time; SCUBE1, signal peptide-CUB-EGF
domain-containing protein 1; SD, standard deviation; WBC, white blood cell count.eligibility of variables. Data in conformity with normal distribution
were analyzed using the Student’s t-test, and those not conforming
to normal distribution using the Mann–Whitney U-test. Data
obtained by measurements are given as the mean  standard
deviation. Data obtained by counting are given as numbers with
percentages; analyses were performed using the Chi-square test. The
area under the receiver operating characteristics (ROC) curve was
used to calculate the discriminative ability of SCUBE1 to determine
patients with CCHF. Sensitivity, speciﬁcity, the negative predictive
value (NPV), and the positive predictive value (PPV) were calculated
according to ROC curves for SCUBE1. A p-value of <0.05 was
considered signiﬁcant.
3. Results
Two hundred ﬁve consecutive patients with CCHF, 103 female
and 102 male, with a mean age of 48.3  16.7 years, were included
in the study. The control group consisted of 76 individuals (41 female
and 35 male), with a mean age of 42.2  13.4 years. One hundredFigure 2. SCUBE1 values for the control group and CCHF patients with and without
hemorrhage.
Figure 3. ROC curve analysis of CCHF patients’ SCUBE1 values by presence of
hemorrhage.
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of tick bite was established in 147 patients. Fever (88.8%), headache
(68.3%), nausea (68.3%), myalgia (81.5%), vomiting (28.3%), and
bleeding (21.0%) were observed in these patients. A SCUBE1 value of
272.0  89.0 ng/ml was determined in the CCHF patients and of
119.4  55.7 ng/ml in the control group (p = 0.0001). While the
SCUBE1 value was negatively correlated with PLT, it was positively
correlated with AST, ALT, CPK, LDH, BUN, Cr, aPTT, and D-dimer values
(Table 1). When the SCUBE1 results were analyzed using the ROC
curve method, the optimum diagnostic cut-off point was 165 ng/ml,
the area underneath the ROC curve (AUC) was 0.929 (95% conﬁdence
interval (CI) 0.865–0.969), sensitivity 89.5%, speciﬁcity 91.7%, PPV
95.8%, and NPV 80.5% (Figure 1).
The mean SCUBE1 value in patients with hemorrhage was
326.3  84.5 ng/ml, compared to 234.7  71.7 ng/ml in patients
without hemorrhage (p = 0.0001) (Figure 2). On ROC curve analysis of
SCUBE1 values, the optimum diagnostic cut-off point was determined
to be 292 ng/ml and AUC was 0.785 (95% CI 0.675–0.871). This cut-off
point SCUBE1 value had a sensitivity of 67.7%, speciﬁcity 80%, PPV
70%, and NPV 78.3% for potentially identify hemorrhagic patients
(Figure 3).Figure 4. SCUBE1 values for the surviving and fatal CCHF cases.Seven of the patients died. A SCUBE1 value of 351.3  68.2 ng/ml
was determined in the patients who died, and of 264.0  87.3 ng/ml
in the survivors (p = 0.012) (Figure 4). In terms of mortality, when the
SCUBE1 results were analyzed using the ROC curve method, the
optimum diagnostic cut-off point was determined to be 310 ng/ml,
AUC 0.791 (95% CI 0.682–0.876), sensitivity 71.4%, speciﬁcity 72.5%,
PPV 20.8%, and NPV 96.2%.
4. Discussion
SCUBE1 is a new biomarker, and no studies on its use in CCHF
are as yet available. SCUBE1 appears to be expressed selectively in
the endothelium.8,9 In situ hybridization has demonstrated
SCUBE1 expression in the vascular endothelium lining the arteries,
veins, and microvessels of all organs examined.8 Increased SCUBE1
levels have been reported in diseases such as acute coronary
syndromes and acute ischemic stroke, which impact on the
endothelium.3 SCUBE1 levels were also found to be elevated in
gastric cancer and hemodialysis patients compared to control
groups.10,11 In this study, the SCUBE1 values of patients with CCHF
were higher than those of the controls (p = 0.0001). A cut-off value
of 165 ng/ml for SCUBE1 was associated with 89.5% sensitivity and
91.7% speciﬁcity, with an NPV of 80.5% and PPV of 95.8%. While
there was a negative correlation between SCUBE1 values and PLT,
there was a positive correlation between SCUBE1 and AST, ALT,
CPK, LDH, BUN, Cr, aPTT, INR, and D-dimer. Dai et al. determined
that both acute coronary syndromes and acute ischemic stroke
were independent predictors of elevated plasma SCUBE1 concen-
trations.3 According to our results, high SCUBE1 levels would seem
to be a marker for CCHF.
Patients with CCHF may present with a clinical proﬁle spectrum
varying from mild to fatal.4,12,13 Mortality is particularly high
following massive hemorrhages resulting from thrombocytopenia
and endothelial dysfunction.4,12 The prediction of hemorrhage is
important for replacement of blood and blood products, supportive
treatments, and the preparation of intensive care conditions.
SCUBE1 levels in the patients when they ﬁrst presented to the
hospital were over 292 ng/ml, and this could predict possible
hemorrhage with 67.7% sensitivity and 80% speciﬁcity. This will
help clinicians to plan treatment and make efﬁcient use of
available equipment.
Increased SCUBE1 levels may also facilitate the prediction of
mortality. In our study, SCUBE1 levels over 310 ng/ml indicated
mortality with 71.4% sensitivity and 72.5% speciﬁcity. Dai et al.
reported that SCUBE1 levels are a prognostic biomarker for acute
coronary syndromes and acute ischemic stroke.3 Prediction of the
prognosis of the disease may be vital in ensuring intensive support
treatment after the ﬁrst day of hospitalization.
In conclusion, SCUBE1 levels may be a novel biomarker for the
prediction of severity of disease in patients with CCHF when
presenting to the hospital. The use of SCUBE1 levels for prognosis
may be possible; further studies with SCUBE1 measurements
taken at different periods of the disease are required. Additionally,
SCUBE1 can predict the disease course in patients with CCHF and
guide the clinician throughout treatment.
4.1. Limitations
The major limitation of the current study is the relatively small
number of patients and controls involved. However, in terms of the
novel ﬁnding that SCUBE1 is a new prognostic biomarker, our
study can be considered a pioneering work in the ﬁeld and can
serve to prompt further comprehensive studies.
In conclusion, SCUBE1 levels may be a good biomarker for the
prediction of the prognosis and severity of disease in patients with
CCHF when presenting to the hospital.
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